CTMX News and Press, CytomX Therapeutics Inc. From 11/18/25

2025-11-18 09:32:02 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: CytomX Therapeutics: Leaning Into The Hype, But What's Next?

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at th...

2025-11-11 04:04:29 ET Antibody-drug conjugates ((ADC)) are antibodies that bind a specific protein while carrying an active agent. ADCs are mostly used in cancer therapy: While targeting a specific protein expressed by the cancer cells, ADC allows the delivery of a highly toxic drug su...

2025-11-07 14:26:56 ET More on CytomX CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible CytomX: A Fresh Start With New Drugs After Total Pipeline Failure CytomX GAAP E...

2025-11-07 14:26:13 ET CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST... Read the full article on Seeking Alpha For further details see: CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript

2025-11-06 16:26:26 ET More on CytomX CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible CytomX: A Fresh Start With New Drugs After Total Pipeline Failure CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthca...

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

2025-11-04 15:15:35 ET Biotech stocks are showing signs of recovery after years of underperformance, supported by successful drug launches, faster FDA approvals, strong trial results, and falling interest rates. M&A activity has picked up and lifted biotech stocks in general as inve...

- CX-801 (PROBODY ® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA ® ...